References
- Richards JB , ZhengHF, SpectorTD. Genetics of osteoporosis from genome-wide association studies: advances and challenges. Nat. Rev. Genet.13(8) , 576–588 (2012).
- Diez-Perez A , AdachiJD, AgnusdeiD et al. Treatment failure in osteoporosis. Osteoporos. Int. 23(12) , 2769–2774 (2012).
- Ralston SH , UitterlindenAG. Genetics of osteoporosis. Endocr. Rev.31(5) , 629–662 (2010).
- Estrada K , StyrkarsdottirU, EvangelouE et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44(5) , 491–501 (2012).
- Mencej S , AlbaghaOM, PrezeljJ, KocjanT, MarcJ. Tumour necrosis factor superfamily member 11 gene promoter polymorphisms modulate promoter activity and influence bone mineral density in postmenopausal women with osteoporosis. J. Mol. Endocrinol.40(6) , 273–279 (2008).
- Body JJ , BergmannP, BoonenS et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos. Int. 21(10) , 1657–1680 (2010).
- Reginster JY . Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs71(1) , 65–78 (2011).
- Venegas KR , GomezMA, GarreMC, SanchezAG, Contreras-OrtegaC, HernandezMA. Pharmacogenetics of osteoporosis: towards novel theranostics for personalized medicine? OMICS16(12) , 638–651 (2012).
- Gennari L . Pharmacogenomics of osteoporosis. Clin. Rev. Bone Miner. Metab.8 , 77–94 (2010).
- Marini F , BrandiML. Pharmacogenetics of osteoporosis: what is the evidence? Curr. Osteoporos. Rep.10(3) , 221–227 (2012).
- Riancho JA , HernandezJL. Pharmacogenomics of osteoporosis: a pathway approach. Pharmacogenomics13(7) , 815–829 (2012).
- Rojo Venegas K , Aguilera Gomez M, Eisman JA, Garcia Sanchez A, Faus Dader MJ, Calleja Hernandez MA. Pharmacogenetics of osteoporosis-related bone fractures: moving towards the harmonization and validation of polymorphism diagnostic tools. Pharmacogenomics11(9) , 1287–1303 (2010).
- Trdan Lusin T , MrharA, StiegerB et al. Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Transl Res. 160(4) , 298–308 (2012).
- Trdan Lusin T , StiegerB, MarcJ et al. Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene. J. Transl. Med. 10 , 76 (2012).
- Trontelj J , MarcJ, ZavratnikA, BogatajM, MrharA. Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol.67(4) , 437–444 (2009).
- Rizzoli R , ReginsterJY, BoonenS et al. Adverse reactions and drug–drug interactions in the management of women with postmenopausal osteoporosis. Calcif. Tissue Int. 89(2) , 91–104 (2011).
- Siris ES , SelbyPL, SaagKG, BorgstromF, HeringsRM, SilvermanSL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am. J. Med.122(2 Suppl.) , S3–S13 (2009).
- Sarasquete ME , Garcia-SanzR, MarinL et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112(7) , 2709–2712 (2008).
- Nicoletti P , CartsosVM, PalaskaPK, ShenY, FloratosA, ZavrasAI. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist17(2) , 279–287 (2012).